Building Japan’s Regenerative Medicine Supply Chain through a Strategic Partnership with Cryoport
First written in FY2021-Q2. 2 of 3 entries say "Restated". Latest entry: FY2022.
0 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「We will achieve highly precise traceability from pharmaceutical companies through to patients.」
The company continues to build a highly precise supply chain for regenerative medicine and pharmaceutical logistics through partnerships with Cryoport and others and the development of temperature-monitoring loggers. - FY2021RestatedAnnual report
「In August 2020, we agreed to a strategic partnership with Cryoport, Inc. (Tennessee, U.S.), which provides superior supply chain solutions globally, including ultra-low-temperature logistics, to build a regenerative medicine supply chain in Japan.」
The company continues to pursue its policy of building Japan’s regenerative medicine supply chain through its strategic partnership with Cryoport. - FY2021-Q2First statedAnnual report
「As part of this initiative, in August 2020 we agreed to a strategic partnership with Cryoport, Inc. (Tennessee, U.S.), which provides superior supply chain solutions globally, including ultra-low-temperature logistics. Through this partnership, we will combine the strengths of both companies and seek to provide highly reliable, seamless distribution services to biopharmaceutical companies.」
In August 2020, the company agreed to a strategic partnership with Cryoport and aims to build distribution services for regenerative medicine in Japan by combining the two companies’ ultra-low-temperature logistics and supply chain capabilities.